Advanced therapy CDMO market seen growing to $12.55 billion by 2030

The advanced therapy medicinal products contract development and manufacturing organization market is forecast to expand from $6.2 billion in 2025 to $12.55 billion by 2030, driven by rising clinical trials, gene and cell therapy adoption, and demand for scalable manufacturing. North America led the market in 2025, while Asia-Pacific is expected to grow fastest over the forecast period.

Why it matters: - The advanced therapy medicinal products CDMO market sits at the center of gene, cell, and tissue-engineered therapy development. - Faster growth in this market signals more outsourcing by biopharmaceutical firms and more demand for specialized manufacturing capacity. - The market’s expansion also tracks with the push to bring complex therapies from lab to clinic and eventually to commercial supply.

What happened: - The Business Research Company said the advanced therapy medicinal products contract development and manufacturing organization market is projected to grow from $6.2 billion in 2025 to $7.24 billion in 2026. - The report forecasts the market will reach $12.55 billion by 2030. - The company projects a 14.8% compound annual growth rate during the forecast period. - The report is titled Advanced Therapy Medicinal Products Contract Development Global Market Report 2026 – Market Size, Trends, And Forecast 2035. - The report covers markets in Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - Download a free sample of the report. - View the full market report.

The details: - The market’s recent growth reflects scarce specialized CDMO services, higher R&D spending in advanced therapies, early adoption of gene and cell therapies, more complex diseases, and the rise of small biotech firms. - The forecast period is supported by scalable manufacturing technologies, stronger CDMO-pharma collaborations, and growth in autologous and allogeneic therapies. - The report flags growing global demand for personalized medicines as another growth driver. - Key trends include broader use of gene, cell and tissue-engineered therapies, tighter regulatory compliance and quality assurance, more outsourced manufacturing, and flexible manufacturing platforms. - The report describes an advanced therapy medicinal products CDMO as a specialized partner that provides expertise, infrastructure and resources for development and production. - The role of the CDMO is to support advanced therapy development and help move treatments from concept to market efficiently. - Rising clinical trial activity is a major demand driver because advanced therapies require specialized manufacturing support. - Clinical trial data also helps optimize manufacturing processes for scalability and product quality across clinical and commercial supply.

Between the lines: - The report points to a market moving from niche capacity toward a more industrialized advanced-therapy supply chain. - North America led the market in 2025 because of its pharmaceutical and biotech infrastructure. - Asia-Pacific is expected to be the fastest-growing region, suggesting manufacturing and development activity is broadening beyond established hubs. - In July 2024, the Royal Pharmaceutical Society reported UK clinical-trial recruitment reached 349,019 in 2023/2024, up from 342,390 the year before. - That increase underscores the broader clinical development pipeline feeding demand for CDMO services.

What's next: - The report expects continued adoption of scalable and flexible manufacturing models as advanced therapy pipelines mature. - More partnerships between CDMOs and drugmakers are likely as companies seek to reduce internal manufacturing bottlenecks. - Regulatory and quality requirements will remain central as more cell and gene therapies move toward commercialization. - Regional growth outside North America could intensify as Asia-Pacific expands its share of the market.

The bottom line: - Advanced therapy CDMOs are becoming a bigger part of the drug development ecosystem, and the market’s projected climb to $12.55 billion by 2030 reflects that shift.